Microba Life Sciences (ASX:MAP) said new data showed the ability of its MetaPanel test to identify clinically significant pathogens missed by standard diagnostic approaches, according to a Wednesday Australian bourse filing.

The test is a gastrointestinal pathogen detection panel that screens for 115 pathogens and virulence factors, including bacteria, viruses, and parasites.

Analysis of 889 MetaPanel tests from a patient cohort characterized by long-term gastrointestinal symptoms showed 20% of patients tested positive for a pathogen that can cause gastrointestinal infection. Meanwhile, 58.3% of tests reveal abnormal microbiome results, supporting referral to a MetaXplore test for further investigation.

Around 78.4% of the pathogens detected by the MetaPanel test are often missed by routine pathology tests, per the filing.

Its shares fell 3% on market close Wednesday.